Seeking Alpha

Baxter (BAX) agrees to pay Onconova Therapeutics $50M upfront for the European commercialization...

Baxter (BAX) agrees to pay Onconova Therapeutics $50M upfront for the European commercialization rights for rigosertib, a compound in Phase III trials for treating rare hematologic (blood) malignancies and in Phase II/III trials for pancreatic cancer. Baxter may also pay up to $515M in pre-commercial development and regulatory milestones, as well as sales milestones and royalties. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector